Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07433023 · ClinicalTrials.gov registry record · Phase 2

tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy

A Phase 2 study, sponsored by Shirley Ryan AbilityLab.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target

NCT07433023: Recruiting Phase 2 study, sponsored by Shirley Ryan AbilityLab.

NCT07433023 is a Phase 2 study that is actively recruiting participants, run by Shirley Ryan AbilityLab. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07433023, a Phase 2 study, is actively recruiting participants, sponsored by Shirley Ryan AbilityLab.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target

Study Summary

This is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the spinal stimulation to further affect mobility outcomes.

Primary Outcome

For Aim 1 participants (GMFCS levels 1-3), an instrumented gait-mat will be used to assess spatiotemporal gait symmetry.

Interventions

  • DRUG 5-Azacitidine
  • DRUG Mannitol
  • OTHER tSCS
  • OTHER Functional Activity Training

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2026-05-28
Est. Completion 2029-01-01
Phase Phase 2
Shirley Ryan AbilityLab

138 total trials

What NCT07433023 shows while recruiting

NCT07433023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).

The record links to 0 conditions, and to 4 interventions - of which 5-Azacitidine is the first listed.

NCT07433023 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07433023 about?

NCT07433023 is a clinical study titled "tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy". This is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participants will also have the...

What is the current status of trial NCT07433023?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-05-28. Estimated completion is 2029-01-01.

What interventions are being tested in trial NCT07433023?

The interventions under investigation include: 5-Azacitidine (DRUG), Mannitol (DRUG), tSCS (OTHER), Functional Activity Training (OTHER).

Who is sponsoring clinical trial NCT07433023?

This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07433023's enrollment target sits among peer trials

80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07433023, the US trial registry maintained by the National Library of Medicine. NCT07433023 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.